Second Division of Cardiology, Cardiothoracic and Vascular Department, University Hospital of Pisa, Pisa, Italy.
Second Division of Cardiology, Cardiothoracic and Vascular Department, University Hospital of Pisa, Pisa, Italy.
Heart Rhythm. 2015 Mar;12(3):580-587. doi: 10.1016/j.hrthm.2014.12.013. Epub 2014 Dec 10.
Riata (RT) and Sprint Fidelis (SF) leads were recalled by the United States Food and Drug Administration because of an increased rate of failure mainly due to conductor fracture or insulation abrasion. According to lead design and type of failure, extraction complexity may be different, potentially affecting procedural outcomes and indications.
The purpose of this study was to assess the extraction profile of RT leads with and without cable externalization in comparison to SF leads.
From January 1997 to April 2014, all consecutive RT and SF leads extracted transvenously were analyzed. Among 661 consecutive patients with 705 ventricular implantable cardioverter-defibrillator (ICD) leads extracted, 194 patients with 134 RT leads (RT group) and 61 SF leads (SF group) were identified. Removal indications often were infective (64%), and extracted leads had a prevalence of dual-coil design (89%). Baseline patients and lead characteristics were comparable between groups.
Success rate was high in both groups (97.8% RT vs 100% SF) without major complications. Mechanical dilation was comparable between groups, but RT leads often required larger sheaths (11.7 ± 1.4 vs 11.3 ± 1.4), a more frequent crossover to the internal transjugular approach (14% vs 3%), and a longer procedural time (23 ± 33 minutes vs 12 ± 16 minutes). Implantation time (odds ratio 4.84, 95% confidence interval 1.05-22.2, P = .042) and RT leads (odds ratio 1.04, 95% confidence interval 1.02-1.06, P <.001) were independent predictors of the internal transjugular approach.
Extraction of RT leads is feasible and effective. However, extraction of RT leads is more complex than that of SF leads. Lack of coil backfilling and cable externalization in RT group may account for these differences.
由于导体断裂或绝缘磨损导致故障发生率增加,美国食品和药物管理局召回了 Riata(RT)和 Sprint Fidelis(SF)导联。根据导联设计和故障类型,提取的复杂性可能不同,这可能会影响程序的结果和适应证。
本研究旨在评估带和不带电缆外露的 RT 导联与 SF 导联相比的提取情况。
从 1997 年 1 月至 2014 年 4 月,对所有经静脉提取的连续 RT 和 SF 导联进行了分析。在 661 例连续接受 705 例心室植入式心脏复律除颤器(ICD)导联提取的患者中,识别出 194 例患者(RT 组)和 61 例 SF 导联(SF 组)的 134 个 RT 导联。移除适应证通常为感染性(64%),提取的导联具有双线圈设计的流行率(89%)。两组患者和导联特征基线无差异。
两组成功率均很高(97.8% RT 与 100% SF),无重大并发症。两组机械扩张率相当,但 RT 导联通常需要更大的鞘管(11.7 ± 1.4 比 11.3 ± 1.4),更频繁地交叉到经颈内静脉入路(14% 比 3%),以及更长的手术时间(23 ± 33 分钟比 12 ± 16 分钟)。植入时间(优势比 4.84,95%置信区间 1.05-22.2,P =.042)和 RT 导联(优势比 1.04,95%置信区间 1.02-1.06,P <.001)是经颈内静脉入路的独立预测因素。
RT 导联的提取是可行和有效的。然而,RT 导联的提取比 SF 导联更为复杂。RT 组中缺乏线圈填充和电缆外露可能导致了这些差异。